SK Bioscience announced on Dec. 24 that it has signed a contract manufacturing organization (CMO) and licensing deal with Novavax for the production and global supply of the U.S. biotechnology company’s COVID-19 vaccine NVX-CoV2373. The contract will run until December next year.
Under the contract, SK bioscience will reserve significant additional manufacturing capacity to produce antigen, a key component of NVX-CoV2373, through 2022, with the possibility to extend the arrangement.
The agreement between the companies also builds on a previously announced advance purchase agreement (APA) between SK bioscience and the Korean government to supply 40 million doses of NVX-CoV2373 for the Republic of Korea. SK bioscience may supply additional quantities of NVX-CoV2373 in the Korean market in 2022….
